Pharma tax inversion 'virus' threatens US economic health
This article was originally published in Scrip
Executive Summary
For biopharmaceutical firms and other companies considering engaging in the practice known as inversion, Senator Charles Schumer (Democrat-New York) has a message: To continue to have access to the American market, workforce and economy "you're going to have to pay your fair share of US taxes."